Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $158.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 112.00% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Raymond James Financial reiterated a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Wedbush boosted their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $129.83.

Dianthus Therapeutics Trading Down 0.3%

Shares of NASDAQ:DNTH traded down $0.23 on Thursday, reaching $74.53. The company had a trading volume of 943,572 shares, compared to its average volume of 930,368. Dianthus Therapeutics has a 52-week low of $32.22 and a 52-week high of $117.88. The firm’s 50 day simple moving average is $100.75 and its 200-day simple moving average is $94.49. The firm has a market capitalization of $4.08 billion, a PE ratio of -17.96 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities research analysts predict that Dianthus Therapeutics will post -3.81 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, SVP Adam M. Veness sold 16,167 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the transaction, the senior vice president directly owned 3,833 shares in the company, valued at approximately $423,086.54. This represents a 80.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Edward Carr sold 20,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the transaction, the chief accounting officer owned 20,000 shares of the company’s stock, valued at $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 242,429 shares of company stock valued at $26,118,913. 3.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. grew its stake in Dianthus Therapeutics by 160.9% during the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after buying an additional 451,597 shares during the period. Sax Wealth Advisors LLC acquired a new stake in shares of Dianthus Therapeutics during the third quarter valued at about $203,000. GAMMA Investing LLC grew its stake in shares of Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after acquiring an additional 254 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Dianthus Therapeutics by 5.7% during the second quarter. Arizona State Retirement System now owns 10,141 shares of the company’s stock valued at $989,000 after acquiring an additional 546 shares in the last quarter. Finally, Nykredit A S acquired a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $147,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.